stockrow
Friday 6 November 2026
Export RGEN’s income statement to Excel — free account
Repligen Corporation
RGEN Healthcare Medical Instruments & Supplies
Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024.
- Revenue
- +10.9%
- EPS
- −351.9%
- Free cash flow
- −11.5%
- Total debt
- +3.28%
Quarter to September 2026, against a year earlier
172.26
3.78
+2.24%
Follow RGEN
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 181.92 | 128.07 | 188.34 |
+8 more quarters Free account |
P/S ratio |
13.50 | 9.80 | 8.70 | 12.48 | |
P/FCF ratio |
193.49 | 126.01 | 119.86 | 215.98 | |
P/Operating CF |
252.26 | 234.93 | 234.66 | 358.49 | |
P/B ratio |
5.20 | 3.64 | 3.15 | 4.38 | |
Price to Tangible BV |
15.85 | 11.84 | 10.53 | 15.22 | |
EV/Sales |
13.20 | 9.56 | 8.48 | 12.27 | |
EV/EBITDA |
68.59 | 46.62 | 40.12 | 60.17 | |
EV/Operating CF |
81.89 | 55.67 | 49.51 | 77.15 | |
EV/FCF |
189.25 | 122.90 | 116.82 | 212.32 | |
Quick Ratio |
8.07 | 7.30 | 7.42 | 6.82 | |
Current Ratio |
9.88 | 9.05 | 9.20 | 8.37 | |
Net Debt/EBITDA |
(11.88) | (5.52) | (5.94) | (5.35) | |
Debt/Assets |
18.99% | 18.68% | 18.65% | 18.38% | |
Debt/Equity |
0.27 | 0.26 | 0.26 | 0.26 | |
Asset Turnover |
0.28 | 0.27 | 0.26 | 0.26 | |
Operating CF/Net income |
(1.12) | 6.54 | 3.40 | 1.93 | |
Capex/Depreciation |
(0.10) | (0.18) | (0.20) | (0.33) | |
Interest Coverage |
(5.17) | 2.47 | 2.86 | 3.25 | |
Research and Development Expense of Revenue |
6.90% | 7.06% | 7.44% | 7.03% | |
Selling, General and Administrative Expense of Revenue |
39.94% | 37.53% | 39.40% | 38.01% | |
Intangible Assets out of Total Assets |
0.48 | 0.50 | 0.50 | 0.51 | |
Share Based Compensation of Revenue |
4.47% | 3.93% | 4.28% | 4.03% | |
Graham Net Nets |
0.04 | 0.05 | 0.05 | 0.03 | |
Graham Number |
0.00 | 25.13 | 27.81 | 27.08 | |
Earnings Yield |
(0.10%) | 0.55% | 0.78% | 0.53% | |
Free Cash Flow Yield |
0.52% | 0.79% | 0.83% | 0.46% | |
Revenue per Share |
3.70 | 3.62 | 3.45 | 3.52 | |
Operating CF per Share |
0.76 | 0.58 | 0.50 | 0.46 | |
Capex per Share |
(0.09) | (0.11) | (0.09) | (0.14) | |
Free Cash Flow per Share |
0.67 | 0.47 | 0.41 | 0.31 | |
Cash per Share |
15.26 | 14.37 | 13.92 | 13.65 | |
Shareholders Equity per Share |
36.98 | 37.44 | 37.36 | 37.45 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
36.98 | 37.44 | 37.36 | 37.45 | |
Free Cash Flow |
37.82 | 26.70 | 23.35 | 17.59 | |
Working Capital |
1,116.30 | 1,067.90 | 1,035.15 | 1,001.56 | |
Capital Expenditures |
(5.28) | (6.07) | (4.95) | (8.11) | |
Net Current Asset Value |
407.31 | 362.41 | 336.05 | 293.82 | |
EV/EBIT |
583.08 | 116.20 | 100.28 | 164.20 | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.04 | |
Price to Operating Income |
596.13 | 119.14 | 102.89 | 167.03 | |
| Other line items | |||||
Average Receivables |
150.10 | 157.33 | 149.48 | 146.35 | |
Average Payables |
28.56 | 29.43 | 30.80 | 31.07 | |
Average Inventory |
171.26 | 171.23 | 166.18 | 156.71 | |
Average Assets |
2,925.06 | 2,925.90 | 2,891.46 | 2,889.68 | |
Average Common Equity |
2,087.41 | 2,086.89 | 2,045.47 | 2,039.42 |
Columns are period end dates · fundamentals updated 5 Nov 2026